

— 2nd Annual International Congress on — **ONCOLOGY PATHOLOGY™**

Towards Harmonization of Pathology and Oncology Standards

UPDATE

A Message From a Co-Chair

Balazs Halmos, MD

Last June, at the inaugural **International Congress on Oncology Pathology™**, I was awestruck by the dedication to patient care and eagerness to learn of all who attended. It's rare that a specialized educational conference like this exists to bring together multiple healthcare professionals, across specialties and disciplines.

In 2017 we started on the path **Towards the Harmonization of Pathology and Oncology**; now in 2018, we must take another step forward.

No two cancers are the same—no two patients. To provide the best possible care for every patient, the collaboration of pathologists and oncologists is indispensable. More than the diagnosis of patients, coordination between team members is vital in determining the course of treatment, monitoring patients, succeeding in surgery, and formulating new ways to approach the way we treat cancer.

This year, at our *2nd Annual* meeting, keynote lectures will cover the role of liquid biopsies in the management of our patients, the latest data on driver mutations and pan tumor predictive biomarkers, and methods to address variations in care across the United States. Whether you treat breast cancers, gastrointestinal cancers, hematologic malignancies, gynecologic or genitourinary disease, or lung cancers—whether you're involved in the management of all of the above—this congress is designed to address challenges you face in clinic.

In a field as fast-paced as oncology, continually learning, integrating what we've learned, and rising to meet new challenges is a skill we've honed over years of practice. In our journey to ever improve patient care, we are not alone. The **International Congress on Oncology Pathology™** is here to help us reach that goal. The next generation of cancer care is here, join us in New York and we'll meet it together!

Sincerely,

Balazs Halmos, MD
Albert Einstein College of Medicine/
Montefiore Medical Center
Bronx, NY



WHAT'S INSIDE

A Message From the Chair	1
A Molecular Approach	1
FEATURE Agenda	2
Liquid Biopsies: The New Frontier	2
Registration Form	3

JOIN US!

Saturday, June 23, 2018

CROWNE PLAZA TIMES SQUARE
1605 BROADWAY
NEW YORK, NY 10019

A Molecular Approach

The classification of tumor and tissue by molecular profiling is an essential aspect to diagnosing, staging, and treating cancer. More than selecting actionable targeted therapies, understanding the underlying makeup of a tumor is an essential aspect in personalizing care for individual patients.

Pathologists are able to use immunohistochemistry to determine protein expression in a given tumor sample; utilize fluorescence in situ hybridization to detect gene translocations, fusions, or amplification on a chromosomal level; measure the level of mutation expression or residual disease through quantitative polymerase chain reactions; and apply the future of detection technology through next-generation sequencing.

In 2018, the use of molecular profiling in cancer is more essential to treatment than ever.

continues on page 2

For more information and to register visit
gotoper.com/go/ICOP18NEWS1





The **International Congress of Oncology Pathology™** agenda will provide attendees various focus topics to bring a greater view of the oncology pathology curriculum.

This year's meeting will include topics such as:

- Multidisciplinary Consultation & Medical Crossfire®
- Optimizing Molecular Testing Selection and Implementation in the Management of CRC
- Clinical Implications of BRCA Assessment for Patients with Ovarian Cancer
- Optimizing Utilization of the Lung Cancer Biopsy
- Refining Management Approaches With Targeted Treatments for Patients with Lung Cancer

See the full agenda at:

gotoper.com/go/ICOP18NEWS1

A Year in Review, continued from page 1

Last year saw the first ever biomarker-based approval in cancer. Pembrolizumab, a PD-1 inhibitor, was approved for the treatment of any and all solid tumors with a microsatellite instability-high (MSI-H) genotype resulting from deficient mismatch repair during DNA replication. MSI-H is the result of a large number of mutations and an actionable target for multiple agents, depending on tumor location. To date, pembrolizumab is the only agent with a pan-tumor indication for MSI-H. This year's **International Congress on Oncology Pathology™** will feature clinical updates on the assessment and targeting of MSI-H in order to address these advancements.

Another class of emerging biomarkers in cancer treatment are NTRK gene fusions. NTRK fusions, which can be treated by tropomyosin receptor kinase (TRK) inhibitors, result in constitutively activated chimeric TRK proteins. The resultant overexpression of kinase function is ultimately oncogenic. Like MSI-H, treatments for NTRK gene fusions have taken a tumor agnostic approach. Understanding the role of TRK inhibition is an essential step in meeting the future of cancer treatment. NTRK and TRK inhibition is just one of the many topics covered at this year's meeting!

Even with the wide-reaching applications described, tumor-specific biomarkers are still an essential aspect of treatment. Breast cancer treatment is dependent on HER2 status, estrogen-receptor status, and progesterone-receptor status. In treating lung cancer, it is essential pathologists and oncologists test for various mutations, including EGFR, ALK, BRAF, and ROS1. These and more are encountered across multiple cancer types, where other biomarkers include RAS, NRAS, PIK3CA, TP53, MET, and so many more. Understanding the role of these mutations in cancer pathogenesis, and integrating the latest clinical data into practice, is an essential skill for all oncologists and pathologists.

Liquid Biopsies: The New Frontier

The world of pathology and patient testing has fundamentally changed with the advent of liquid biopsies. The ability to provide timely and accurate characterization of a tumor, across type and underlying biology, is an essential aspect in properly diagnosing and selecting treatment options for patients.

Liquid biopsies—biopsies of the plasma and blood rather than the tissue—have changed our fundamental approach to diagnosis and monitoring. The use of liquid biopsies is not limited to disorders of the blood, rather liquid biopsies are able to test for cell-free DNA or circulating tumor cells to provide an accurate diagnosis.

As pathology continues to grow and change, special considerations must be made. Which form of testing is preferred and appropriate? When can liquid biopsies replace traditional tumor testing? What role does monitoring through liquid biopsies have in treatment? All these questions and more will be addressed at the **International Congress on Oncology Pathology™** where key experts in lung, breast, gastrointestinal, and other malignancies will provide an overview of the latest clinical data on liquid biopsies, along with detailed case studies, and special considerations for multidisciplinary faculty.



REGISTRATION

First Name _____ Middle Initial _____

Last Name _____ Degree(s) _____

Physician Fellow PA-C NP Pharmacist Other _____

Nursing license _____

Are you employed by a for-profit organization, including biotech, financial, and pharmaceutical, defined as "Industry" by PER®?

Yes No

Address type: Home Hospital Office

Mailing Address _____

City _____ Prov/State _____

Country _____ Postal/Zip Code _____

E-mail (Your confirmation will be sent via e-mail) _____

Will you be attending the CAR T Pre-Conference workshop (included in congress registration fee)?: Yes No

	Advanced	On-Site
<input type="checkbox"/> Physicians	\$99	\$149
<input type="checkbox"/> Nurses, PAs, Other HCPs	\$79	\$129
<input type="checkbox"/> Fellows *	\$79	\$129
<input type="checkbox"/> Industry **	\$299	\$349

*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.

**INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

A cancellation fee of 25% will be assessed on refunds requested through and including **May 11, 2018**, and a 50% fee applies to refunds requested from **May 12, 2018** through **June 9, 2018**. No refunds will be made after **June 9, 2018**. There is no charge for substitution. Substitutions can only be applied to the same conference and only two substitutions will be honored.

Phone type: Home Mobile Work

Phone _____ Fax _____

Specialty _____ Birth Date (MM/DD/YYYY) _____

Institute/Organization _____

Payment can be made by: Check VISA MasterCard Discover American Express

Charge Amount _____

Card Number _____

Expiration Date _____

Name as It Appears on Credit Card _____

Security Code _____

Billing Address of Card (if different from above; zip code required) _____

Signature _____

Four easy ways to register:

- 1) Go to our website at gotoper.com
- 2) Fill out the registration form and mail it with your payment (checks and credit cards are accepted) to the address below. Please make checks payable to "Physicians' Education Resource, LLC - ICOP18."
- 3) Fill out the registration form and fax it to (609) 257-0705 (credit cards only)
- 4) Call (888) 949-0045

Practice Setting:

- Academic medical center/university
- Laboratory/basic research Pharmacy
- Community hospital-based practice
- Government agency
- Community office-based practice
- Pharmaceutical/biotechnology company
- In training (fellow, resident, student)
- Other

What is your principal activity?

- Patient care Clinical research
- Administrative Teaching/training Other

Preferred educational formats:

- Live Online Print

Preferred methods of communication:

- Phone Mail E-mail

Would you like to participate in CME surveys?

Yes No

How many cancer patients do you treat each month? _____

Years practicing medicine _____

Would you like to enroll in the PER Point System?

Yes No

Registration fees include continental breakfasts, breaks, receptions and e-syllabus materials.

All payments must be made by a draft on a United States bank.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

PER® complies with the Physician Payments Sunshine Act as part of the Affordable Care Act. Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the Act.

— 2nd Annual International Congress on —
ONCOLOGY PATHOLOGY™

Towards Harmonization of Pathology and Oncology Standards

UPDATE

2 Clarke Drive, Suite 110
Cranbury, NJ 08512

Phone: (888) 949-0045
E-mail: info@gotoper.com

“ Presenters are very knowledgeable about the current therapies. ”

— 2nd Annual International Congress on —
ONCOLOGY PATHOLOGY™

Towards Harmonization of Pathology and Oncology Standards

Saturday
June 23, 2018

Crowne Plaza Times Square
1605 Broadway
New York, NY 10019

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity is approved for *AMA PRA Category 1 Credit™*.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.
This activity is supported by an educational grant from Genomic Health, Inc.

Meet the Co-Chairs!



Alain Borczuk, MD
Professor of Pathology and
Laboratory Medicine
Vice Chairman for Anatomic
Pathology
Department of Pathology and
Laboratory Medicine
Weill Cornell Medicine
New York, NY



Balazs Halmos, MD
Professor of Clinical Medicine
Director, Thoracic Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of Medicine/
Montefiore
Medical Center
Bronx, NY

For more information and to register visit
gotoper.com/go/ICOP18NEWS1

